Evidence has emerged suggesting a role for the cannabinoid CB 2 receptor in immune cell motility. This provides a rationale for a novel and generalized immunoregulatory role for cannabinoid CB 2 receptor-specific compounds. In support of this possibility, we will review the biology of a class of cannabinoid CB 2 receptor-specific inverse agonist, the triaryl bis-sulfones. We will show that one candidate, Sch.414319, is potent and selective for the cannabinoid CB 2 receptor, based on profiling studies using biochemical assays for 45 enzymes and 80 G-protein coupled receptors and ion channels. We will describe initial mechanistic studies using this optimized triaryl bis-sulfone, showing that the compound exerts a broad effect on cellular protein phosphorylations in human monocytes. This profile includes the down regulation of a required phosphorylation of the monocyte-specific actin bundling protein L-plastin. We suggest that this observation may provide a mechanism for the observed activity of Sch.414319 in vivo. Our continued analysis of the in vivo efficacy of this compound in diverse disease models shows that Sch.414319 is a potent modulator of immune cell mobility in vivo, can modulate bone damage in antigeninduced mono-articular arthritis in the rat, and is uniquely potent at blocking experimental autoimmune encephalomyelitis in the rat.
Introduction
Since its discovery in 1993, the cannabinoid CB 2 receptor has been an appealing therapeutic target for novel immunomodulators. Initial studies suggested that the receptor was not expressed in the central nervous system (Munro et al., 1993) , suggesting that cannabinoid compounds specific for the CB 2 receptor would be free of the neural deficits seen in nonspecific cannabinoid compounds. The high-level expression within immune cells and the inducible expression of the receptor following inflammatory insult suggested that the receptor may serve to mediate the immune regulatory activities described for cannabinoids (Kaplan et al., 2003) . Finally, studies showed that the primary active component in Cannabis, D9-tetrahydrocannabinol (THC), is a partial agonist at the cannabinoid receptor. This observation defined the pharmacology of a preferred therapeutic at the cannabinoid CB 2 receptor.
However, this initial view of the cannabinoid system has proved to be simplistic. Detailed studies of the expression of the cannabinoid CB 2 receptor have shown that functional receptors can be found in neural tissue (Van Sickle et al., 2005; Beltramo et al., 2006; Onaivi et al., 2006) . This may alter the utility of cannabinoid CB 2 receptor-specific compounds. In addition, selected animal models (Smith et al., 2000 (Smith et al., , 2001 Croci et al., 2003; Benamar et al., 2007) have suggested that cytokine levels can be mediated by manipulation of the cannabinoid CB 1 receptor. This suggests that the cannabinoid CB 2 receptor may not be the only cannabinoidbased mediator of the immune system, and may explain the fact that the cannabinoid CB 2 receptor-deficient mice fail to show significant immune deficit under standard conditions (Buckley et al., 2000; Ofek et al., 2006) . Finally, other components of Cannabis, including cannabidiol, have proved to be potent immunomodulatory compounds (Malfait et al., 2001; Costa et al., 2004; Giudice et al., 2007) . Recent evidence has shown that this compound behaves as an inverse agonist to the cannabinoid CB 2 receptor in standard biochemical assays (Thomas et al., 2007) .
Taken together, these observations may suggest the value of adopting a broad view when considering the desired pharmacology of an immune therapeutic based on the cannabinoid CB 2 receptor.
Into this arena enters cannabinoid CB 2 receptor-specific triaryl bis-sulfones. In this review, we will discuss the biology of this novel class of cannabinoid CB 2 receptor-specific inverse agonists. We will further document the specificity of a member of this class, and describe a biology based on the ability of these compounds to modulate immune cell migration. We will provide initial data providing a potential mechanism for the activity of these compounds, based on controlling the phosphorylation required for activity of an actin bundling protein. Finally, we will describe the activity of an optimized triaryl bissulphone, Sch.414319, in arthritis and in experimental autoimmune encephalomyelitis (EAE). The ability of these compounds to modulate EAE mimics a diminished disease observed in animals lacking the cannabinoid CB 2 receptor. We conclude that cannabinoid CB 2 inverse agonists may play a part in the therapeutic pharmacopoeia that targets this class of receptors.
Identification and initial biochemistry of triaryl bis-sulphones
Triaryl bis-sulphones were identified from a compound library screening campaign, in which compounds were tested for a selective ability to block binding of [ 3 H]-CP55,940 to membrane preparations expressing recombinant human cannabinoid CB 2 receptor versus membrane preparations expressing recombinant human CB 1 receptor (Lunn et al., 2006a) .
The ability of the identified triaryl bis-sulphones to decrease basal binding of [ 35 S]-GTPgS to recombinant cell membranes expressing cannabinoid CB 2 (and CB 1 ) receptors, to bind with an increased potency to recombinant cell membranes in the presence of 100 mM GTPgS, and to decrease forskolin-stimulated cAMP levels in cells expressing the recombinant receptor are consistent with an inverse agonist pharmacology (Greasley and Clapham, 2006) . This pharmacology has been maintained throughout an extensive medicinal chemistry effort designed to improve the pharmacological characteristics of triaryl bis-sulphones (Lavey et al., , 2007 Shankar et al., 2005) . An optimized compound, designated Sch.4141319, was engineered to contain a terminal trifluoromethane sulphonamide to permit salt formation and optimize solubility. This resulted in a compound that exhibited superior blood levels when dosed orally in rats (Table 1) .
Our initial screening studies of Sch.414319 showed that the compound was specific for the CB 2 receptor over the CB 1 receptor. However, an optimized therapeutic candidate requires data demonstrating significant selectivity over additional enzymes and receptors separate from the target receptor. To this end, we carried out a generalized evaluation to investigate whether any activity identified for the optimized triaryl bissulphone Sch.414319 could result from a high-affinity interaction with some off-target effectors. Sch.414319 was submitted to MDS Pharma Services for testing its ability to modulate the activity of a broad collection of receptors and enzymes. The selected panel of proteins and receptors (Table 2 ) included 45 enzymes (including 11 kinases), 80 G-protein-coupled receptors and ion channels, and three recombinant cell-based adhesion inhibition assays mediated by fibronectin, VCAM-1 and ICAM-1. Eight of these biochemical screening assays were judged to be affected by the addition of 10 mM Sch.414319, showing greater than 50% inhibition (Table 2) . These selected assays were retested using a four-point logarithmic dilution series of Sch.414319 to generate an estimation of compound potency in eight identified assay systems. As expected, Sch.414319 blocked binding of [ 3 H]-WIN55,212-2 to the human cannabinoid CB 2 receptor (K i E70 nM). The compound also blocked binding to the L-type calcium channels that measured using radiolabelled dihydropyridine (K i E0.44 mM), phenylalkylamine (K i E2.43 mM) and benzothiazepine (K i E6.07 mM). The compound also bound with modest affinity to several other receptor preparations, including the thromboxane A2 receptor (K i E1.44 mM), the non-selective sigma receptor (K i E2.05 mM) and the cholecystokinin B type (CCKB) receptor (K i E5.7 mM). Although this analysis is not exhaustive, it provides additional evidence that the biology of Sch.414319 is mediated primarily by the cannabinoid CB 2 receptor.
Cell biology of triaryl bis-sulphones
A number of biochemical and cellular activities associated with immune modulation by cannabinoids have been ascribed to the cannabinoid CB 2 receptor (Kaplan et al., 2003) . Some of the activities require high cannabinoid concentrations that are unexpected for cannabinoid receptor-mediated events. Indeed, several laboratories have reported cannabinoid effects that are mediated by such alternative mechanisms (Kraft et al., 2004; Curran et al., 2005; Kaplan et al., 2005; McCollum et al., 2007) . We believe this set of observations speaks for the complexity of cannabinoid biology, and supports the value of considering novel pharmacological entities in targeting the cannabinoid CB 2 receptor.
An initial set of experiments were planned to test whether triaryl bis-sulphones could function as antagonists in several cannabinoid-induced in vitro and in vivo cytokine production (Lunn et al, 2006a, b) . The pharmacokinetic profiles of orally administered drug candidates were approximated by monitoring the plasma concentration versus time after dosing and calculating the area under the curve (AUC). For these determinations, rats were orally dosed at 10 mg kg À1 (in 0.4% w/v methylcellulose). Plasma levels were sampled (3 times per day, n ¼ 3) and drug levels determined using standard quantitative HPLC methodologies (Cox et al., 1999) . systems. We were unable to demonstrate an effect of the compounds on human peripheral blood mononuclear cell and murine T-cell proliferation, T-cell and monocyte cytokine production, and surface-marker upregulation-the compounds were either inactive or demonstrated limited activity at concentrations 45 mM, deemed inconsistent with a CB 2 receptor-mediated response (data not shown; Lunn et al., 2006a, b) . As part of this effort, we evaluated the effect of WIN 55212-2 and HU-210 on lipopolysaccharide-induced cytokines in Corynebacterium parvum-primed and unprimed mice. As hoped, the compounds modified inflammatory cytokine levels, decreasing serum tumour necrosis factor-and interleukin-12, and increasing interleukin-10 ( Smith et al., 2000) . However, the compounds appeared to function through the cannabinoid CB 1 receptor. Consistent with this conclusion, the cannabinoids showed similar cytokine responses at significantly lower doses when administered intracerebroventricularly, (Smith et al., 2001) .
We next examined the ability of triaryl bis-sulphones to control immune cell movement. Modulating immune cells' migration to the site of inflammatory insult has been a powerful driving force behind campaigns to develop chemokine antagonists (De Clercq, 2003; Horuk, 2003; Chen et al., 2004) . Such chemokine receptor antagonists have shown promise for the treatment of asthma (Varnes et al., 2004) and chronic obstructive pulmonary disease, arthritis and reperfusion injury (Widdowson et al., 2004) . Other laboratories have suggested a link between the cannabinoid CB 2 receptor and cellular movement. Cannabinoids have been demonstrated to mediate cell migration in a variety of cells, including myeloid leukaemic cell line 32D/G-CSF-R, isolated mouse splenocytes (Jorda et al., 2002) , 1,25-(OH) 2 vitamin D 3 -treated HL-60 cells , EoL-1 human eosinophilic leukaemia cells and human peripheral blood eosinophils (Oka et al., 2004) . However, the mechanism by which cannabinoids mediate this effect is complex. In many of the above papers, cannabinoids are shown to attract cells expressing the receptor. This suggests that cannabinoid agonists may be the therapeutically relevant class of compounds. However, cannabinoids upregulated chemokine expression in several cell types (Jbilo et al., 1999; Derocq et al., 2000) . More recently, Coopman et al. (2007) have demonstrated an upregulation of chemokine receptors following T-lymphocyte activation. Adding to this complication, the behaviour of cells exposed to cannabinoid agonists did not mimic the behaviour of chemokines. Lopez-Cepero et al. (1986) showed that THC suppressed macrophage spreading. Sacerdote et al. (2000) argued that the nonspecific cannabinoid agonist CP55,940 blocked both chemokinesis (non-directed cell movement) and N-formyl-methionylleucyl-phenylalanine (fMLP)-induced cellular chemotaxis of rat peritoneal macrophages, with an EC 50 E10-30 nM. Jorda et al. (2002) also argued that chemokinesis played a significant role in this biology-administration of the agonist 2-arachidonoyl glycerol on both sides of the membrane in a transwell chemotaxis chamber generated significant cellular motion to the distal surface. Gokoh used differentiated HL-60 cells to show a time-and dose-dependent increase in F-actin staining (therefore actin polymerization) following 2-arachidonoyl glycerol treatment. This phenotype, abolished when cells were treated with SR144528, was accompanied by the extension of non-directed pseudopods. The investigators suggested the potential involvement of phosphoinositide 3-kinase, Rho-family small G-proteins and a tyrosine kinase in this process. Kurihara et al. (2006) observed a repeating random extension F-actin-containing pseudopods in HL60 cells treated with the cannabinoid CB 2 receptor agonist JWH015 and 2-arachidonoyl glycerol. The activity of RhoGTPase RhoA decreased, and Rac1, Rac2 and Cdc42 activity increased with cannabinoid treatment. These CB 2 receptormediated changes appear to be similar to those observed using the Rho-dependent protein kinase (p160-ROCK) inhibitor Y27632. The authors concluded that the CB 2 receptor might exert an immunomodulatory role by controlling the RhoA-ROCK pathway.
Our initial studies (Lunn et al., 2006) showed that the cannabinoid CB 2 receptor inverse agonist Sch.225336 blocked recombinant cells chemotaxis to 2-arachidonoyl glycerol in vitro, and blocked migration of immune cells to a CC chemokine ligand (CCL)2-soaked gel foam sponge implanted intraperitoneally. We also showed that oral doses of Sch.225336 blocked cell migration into the peritoneal cavity following antigen challenge, and blocked cell migration to the lungs of sensitized mice following an aerosol antigen challenge. Further studies showed that oral administration of a cannabinoid CB 2 receptor-specific triaryl bissulphone blocked cannabinoid-induced migration mediated by HU210, the protein immunogen methylated bovine serum albumin (mBSA), thioglycolate, zymosan and lipopolysaccharide (CA Lunn et al., in press). These results have extended to Sch.414319. Figure 1 shows that oral administration of Sch.414319 blocks accumulation of immune cells into the pleural cavity of sensitized CF1 outbred mice (panel A) and sensitized Sprague-Dawley female rats (panel B) challenged with 200 mg mBSA. In these models, the triaryl bis-sulphone is almost as effective as 10 mg kg À1 rofecoxib.
Likewise, the figure (panel C) shows that oral administration of Sch.414319 blocks lung eosinophilia following aerosol administration of an ovalbumin antigen to ovalbumin/ alum-sensitized male B6D2F1/J mice to an extent comparable to 10 mg kg À1 rolipram. In all cases, Sch.414319 and the control compound was dosed orally in 0.4% methylcellulose at days À2, À1, 1 h before challenge and 3 h post-challenge. Twenty-four hours after challenge, cells were collected from the pleural cavity or from a bronchial alveolar lavage and quantitated. We conclude from these studies and from the results in the literature that immune cell mobility can be modulated through the cannabinoid CB 2 receptor. The mechanism by which the cannabinoid CB 2 receptor is linked to cell motility, and the explanation for the effects of both cannabinoid agonists and inverse agonists on this process remain complex. Chemotaxis involves an interaction between both signalling elements (for example, receptors) and structural elements (linked to maintaining cell polarity), with numerous pharmacological strategies available for modulating the process. A number of neuronal receptor systems have been shown to desensitize chemokine receptors (Zhang and Oppenheim, 2005) . For example, heterologous desensitization of chemokine receptors via opioid receptor signalling has also been documented (for review see Steele et al., 2002) , a desensitization mediated by phosphorylation of the chemokine receptor via calciumindependent protein kinase C isotypes (Ali et al., 1999; Zhang et al., 2003) . Zhang and coworkers have also shown that activation of the A2a adenosine receptors suppresses chemokine receptor function, based on protein kinase Amediated heterologous desensitization (Zhang et al., 2006) . This is believed responsible, in part, for the anti-inflammatory activity of adenosine.
With these thoughts in mind, and the observation that the first cannabinoid CB 2 receptor inverse agonist, the biarylpyrazole SR144528, was shown to alter p42/p44 MAPK signalling mediated by receptors to insulin and LPA (Bouaboula et al., 1999) , we sought to investigate this problem by studying the effect of Sch.414319 on global pattern of protein phosphorylation in isolated immune cells. This decision was stimulated by kinetic experiments showing that initial inhibitory effects we observed on cellular chemotaxis appeared within 30 min of treatment with the cannabinoid receptor inverse agonist (L Bober, data not shown). We also were unable to detect significant changes in proteins synthesized by Jurkat cells treated with 10 nM Sch.414319, as measured by microarray expression profiling (D Lundell, personal communication). Based on these observations, we ruled out a role for new protein synthesis in the biology of Sch.414319 and speculated that the cannabinoid effect was the result of post-translational modification of existing proteins. As an initial test of this hypothesis, we determined the ability of Sch.414319 to modulate cellular protein phosphorylation in peripheral blood mononuclear cells. Peripheral blood mononuclear cells (1 Â 10 7 cells ml À1 )
from normal human volunteers were resuspended in phosphate-free RPMI medium (Invitrogen Corporation, Carlsbad, CA, USA) containing 1% dialyzed foetal bovine serum (Invitrogen, Corporation, Carlsbad, CA, USA), and then treated with 0.5 mCi ml À1 [ 32 P]orthophosphoric acid in the presence or absence of 10 nM Sch.414319 or 10 nM HU210. After incubation at 37 1C for 60 min, cell-free extracts were prepared for two-dimensional sodium dodecyl sulphatepolyacrylamide gel electrophoresis (O'Farrell, 1975) , autoradiography (7-day exposure at À70 1C on Kodak XAR film with intensifier screen) and comparative digital imaging (Kendrick Laboratories Inc., Madison, WI, USA). Figure 2 shows that we successfully visualized a number of phosphorylated proteins from the radiolabelled cell extracts. Comparative digital imaging of the gels detected 21 polypeptides that showed a difference in phosphorylation following cannabinoid treatment (Table 3 ). The cannabinoid agonist HU210 altered phosphorylation of five proteinsthree of these proteins were also affected by the cannabinoid inverse agonist. However, there was no reciprocal relation Figure 1 Sch.414319 modulates cell migration in vivo. Murine delayed type hypersensitivity reaction was carried out using female CF1 mice as described (Fine et al., 2003) . (a) Sensitized female CF1 outbred mice were challenged with vehicle or with mBSA (200 mg). Sch.414319 or rofecoxib (10 mg kg
À1
) was dosed orally in 0.4% methylcellulose at days À2, À1 and 1 h before challenge and 3 h post-challenge. Twenty-four hours after challenge, cells were collected from the pleural cavity and quantitated. (b) Sensitized Sprague-Dawley female rats were challenged with vehicle or with mBSA (200 mg), and then dosed as above. (c) B6D2F1/J mice sensitized with ovalbumin/alum were challenged with aerosolized ovalbumin after dosing with vehicle, Sch.414319 or rolipram, as described above. Twenty-four hours after challenge, total cells and eosinophils (using differential Wright-Giemsa staining) recovered from a broncheoalveolar lavage were quantitated. mBSA, methylated bovine serum albumin. between cannabinoid agonist treatment and the cannabinoid inverse agonist treatment (excepting protein no. 7). Two species (protein no. 71 and protein no. 1) showed equivalent changes with treatment by the agonist and inverse agonist. Two species (protein no. 69 and no. 96) were only affected by the agonist. The majority of the detected differences were seen only with Sch.414319 treatment. Because the cannabinoid inverse agonist does not reverse the phosphorylation pattern of the agonist, we question whether we should expect Sch.414319 to function as a classic inverse agonist-reversing the effects of an agonist. Similarly, the biarylpyrazole cannabinoid CB 2 receptor inverse agonist SR144528 alone failed to induce significant pain hypersensitivity in model systems where cannabinoid CB 2 receptor agonists clearly demonstrate decreased pain sensitivity (see Nackley et al., 2003; Elmes et al., 2004; Hohmann et al., 2004; Beltramo et al., 2006; La Rana et al., 2006; Gutierrez et al., 2007) .
Proteins present in sufficient quantities and showing significant changes in phosphorylation following drug treatment were excised from stained daughter gel sheet, digested with endoproteinase Lys-C and trypsin and the resulting peptides sequenced by matrix assisted laser desorption time-of-flight mass spectrometry (MALDI-MS; Protein Chemistry Core Facility, Columbia University). The majority of the proteins tested could not be resolved from background noise. However, two proteins were identified. Figure 3 shows that analysis of protein no. 61 generated seven peptide sequences consistent with human 14-3-3-e isoform protein (accession number: AAD00026.1) and analysis of protein no. 16 generated eight peptide sequences, consistent with human L-plastin (accession number: P13796; also known as Lymphocyte cytosolic protein 1, LCP-1, LC64P). Examining the biology of these proteins may offer insight into the pathway by which triaryl bis-sulphones regulate cell motility. The first protein, 14-3-3-e is a member of a conserved acidic protein family known to bind a number of signalling proteins, including kinases, phosphatases and transmembrane receptors. With such a broad distribution of activities, the reported association of 14-3-3 protein with the regulation of cell spreading (Rodriguez and Guan, 2005) may reflect the broad regulatory role of this protein rather than a specific role in cannabinoid CB 2 receptor biology.
Of more interest is the modulation of L-plastin phosphorylation by Sch.414319. Plastins are a set of actin-bundling proteins involved in the regulation of the actin cytoskeleton (Delanote et al., 2005) . Three isoforms have been identified. T-plastin is constitutively expressed in epithelial and mesenchymal cells, I-plastin expression is restricted to absorptive intestinal and kidney cells and finally, L-plastin is expressed in hematopoetic cells, and is overexpressed in many solid tumours. Localization studies find L-plastin associated with structures involved in locomotion, adhesion and immune defense, including filopodia and immune complexes (Jones and Brown, 1996; Babb et al., 1997; Samstag et al., 2003) . Recent studies have shown that phosphorylation of Ser5 increases F-actin-binding activity to the periphery of membrane protrusions in Vero cells (Janji et al., 2006) . Boldt et al. (2006) showed that L-plastin is phosphorylated in polymorphonuclear neutrophils upon FPRL-1 activation with 0.1 mM W-peptide (Trp-Lys-Tyr-MetVal-Met-NH2) or 1 mM sCKb1-8 (amino acids 46-137 of the b-chemokine CKb8, whereas other proteins associated with the cytoskeleton (moesin, cofilin and stathmin) are dephosphorylated. Finally, cells expressing a non-phosphorylatable ser5ala mutant of L-plastin showed decreased expressin of CD25 and CD69 at the cell surface , suggesting phosphorylation of L-plastin may control receptor transport to the cell surface.
All of these studies suggest that control of L-plastin phosphorylation may represent a unique mechanism independent of chemokine receptor desensitization by which triaryl bis-sulphones could control of immune cell mobility and immune modulation. This model suggests that the cannabinoid CB 2 receptor-specific triaryl bis-sulphones decreases L-plastin phosphorylation, which decreases the ability to the L-plastin to organize the actin fibrils involved Figure 3 Identification of phosphoproteins selectively modulated by treatment with Sch.414319. Phosphoproteins modulated by treatment of human mononuclear cell preparations with Sch.414319 were detected by two-dimensional sodium dodecyl sulphate-polyacrylamide gel electrophoresis, followed by autoradiography and quantitative digital imaging of the resulting autoradiogram. Proteins present in sufficient quantities and showing significant changes in phosphorylation following drug treatment were isolated from stained daughter gels, digested with endoproteinase Lys-C and trypsin and submitted for sequencing (Protein Chemistry Core Facility, Columbia University). Sequences and sequence alignments derived from the analysis of protein spot no. 61 (a) and protein spot no. 16 (b) are presented as lines under specific protein sequences.
in cellular polarization, required for controlled cellular chemotaxis. We would argue that this biology is not the direct result of inhibition of the kinases involved in L-plastin phosphorylation. Both protein kinase A (Wang and Brown, 1999) and protein kinase C (Paclet et al., 2004) have been implicated in the phosphorylation of L-plastin. We have shown that Sch.414319 does not inhibit the biochemical activity of several protein kinases, including a Ca 2 þ / calmodulin-dependent protein kinase II, epidermal growth factor receptor tyrosine kinase, extracellular signal-regulated kinase 1 serine/threonine kinase, the fyn, HER2 and lck tyrosine kinases, non-selective protein kinase A, a nonselective protein kinase C and selective assays for protein kinase C-, -(I and II) and -( Table 2 ). This suggests that the decreased phosphorylation of L-plastin following triaryl bissulphone treatment is not due to inhibition of these protein kinases independent of cannabinoid CB 2 signalling. The ability of cannabinoid CB 2 receptor-specific triaryl bis-sulphones to modulate plastin phosphorylation may provide a rationale for linking this class of compounds with cancer cell motility (invasiveness). A number of neoplastic cells from solid tumours are shown to express L-plastin, including 68% from carcinoma cell lines and 53% from mesenchymal cell lines (Lin et al., 1993; Park et al., 1994) . The L-plastin promoter has been used to specifically target gene expression to these cells (Chung et al., 1999; Peng et al., 2001; Akbulut et al., 2004) , and in experiments seeking to control invasiveness using antisense RNA (Zheng et al., 1999) . Klemke et al. (2007) showed that L-plastin expression per se did not correlate to the penetration depth or the stage of melanoma in human tissue biopsies. However, in the same paper, Klemke and co-workers did show a correlation between L-plastin phosphorylation and tumour cell invasiveness in vitro and in a mouse B16 melanoma model. While these models are interesting, they are complicated by the biology of L-plastin knockout (LPL À/À ) mice. Chen PMNs. Further studies are needed for comparing this biology with that using small-molecule inhibitors to determine the ultimate mechanism by which cannabinoid inverse agonists function.
Cannabinoid CB 2 receptor and disease: arthritis
The demonstrated ability of triaryl bis-sulphones to modulate immune cell motility provides a generalized, wellvalidated mechanism for generalized immunoregulation. With the identification of Sch.414319 as an optimized member of this compound class, we have confirmed the ability of this compound to modulate cell migration in a number of animal models described previously. Sch.414319 inhibits leukocyte migration into the pleural cavity of mice and rats sensitized to mBSA antigen, and blocks eosinophilia in fluid recovered from the lungs of mice and guinea pigs sensitized to ovalbumin antigen (data not shown). However, we were most interested in determining the ability of this compound to impact a more complex disease modelantigen-induced arthritis. Studies with a congener of Sch.414319, designated Sch.356036, showed that the compound can ameliorate bone damage in a rat model of relapsing-remitting arthritis, a particularly harmful property of this inflammatory joint disease. In leukocyte recruitment models, this CB 2 receptor-selective compound shows efficacy when added in concert with suboptimal doses of selected anti-inflammatory agents, consistent with its unique function and indicative of its potential therapeutic utility (CA Lunn, et al., in press ). The recruitment of inflammatory cells into the joint space has been implicated in the initiation and maintenance of the pannus, a defining characteristic of rheumatoid arthritis. Both T cells (Kraan et al., 2004; Desmetz et al., 2007) and macrophages (Haringman et al., 2005; Szekanecz and Koch, 2007) have been suggested as playing a significant role in the pathology of this disease. The value of chemokine inhibition (Tak, 2006) as well as the ability of current therapeutics to modulate cellular infiltration into the joint (Taylor et al., 2000; Jenkins et al., 2002; Bukhari et al., 2003; Sesin and Bingham, 2005) add to the significance of this therapeutic approach. Based on these data, we sought to evaluate Sch.414319 in a rat model of relapsing-remitting arthritis. For studies using triaryl bis-sulphones, monoarticular arthritis was induced according to described procedures (Buchner et al., 1995) . Male inbred Lewis rats were first sensitized with mBSA in complete Freund's adjuvant injected near the inguinal lymph node. Fourteen days later, arthritis was induced by injecting 500 mg of a sterile mBSA solution in a volume of 5 ml into the left talar-navicular joint space of animals anesthetized with isofurane vapors. The right paw was similarly injected with sterile saline to serve as an internal control. All animals are acclimated to treatment regime by dosing for two days before disease induction. Animals were handled in accordance with protocols and guidelines established by our institution's Animal Care and Use Committee, and showed no weight loss during progression of the monoarticular arthritis. Figure 4 shows that oral administration of 10 mg kg À1 Sch.414319 2 days before through 5 days after antigen challenge showed improved bone damage score when measured 2 weeks after the last drug dose. The effect was similar to that seen with 3 mg kg
À1
rofecoxib. This result suggests that treatment with Sch.414319 slowed the development of the antigen-induced monoarticular arthritis, perhaps by slowing the movement of immune cells to the talar-navicular joint space. This fact and the ability of triaryl bis-sulphones to synergize with other anti-inflammatory agents including the cyclooxygenase inhibitor piroxicam, the PDE4 inhibitor rolipram and the steroid dexamethasone, provide a potential use for the class of compound (CA Lunn, et al., in press ). The ability to modulate the effects of antigen insult on bone structure using two cannabinoid CB 2 receptor inverse agonists (Sch.414319 and Sch.356036 ) suggests a link between this receptor and bone physiology. However, mimicking the complex role of cannabinoid CB 2 receptor pharmacology in cell migration, the role of the cannabinoid CB 2 receptor in bone physiology is complex. Idris et al. (2005) have reported that CB 2 (and CB 1 ) receptor antagonists/inverse agonists AM630 and SR144528 inhibited osteoclast formation in C57BL/6 cell cultures stimulated with RANKL and M-CSF-agonists stimulated osteoclast formation. This result is consistent with the benefit of inverse agonists in maintaining bone density. On the other hand, a study of 388 postmenopausal women showed a significant association of polymorphisms and haplotypes containing the CB 2 receptor gene CNR2 on human chromosome 1p36 with osteoporosis (Karsak et al., 2005) . Assuming that the mutations detected in this study would decrease expression or activity of the CB 2 receptor, Karsak suggested the data are consistent with the value of a cannabinoid CB 2 receptor agonist as a valuable therapeutic. Ofek et al. (2006) also reported that, while young mice appeared normal, aged (1 year old), CB 2 receptor-deficient mice exhibited an accelerated trabecular bone loss and cortical expansion. He also showed that the cannabinoid CB 2 receptor-specific agonist HU308 stimulated proliferation of osteoblastogenic cultures and restricted osteoclastogenic cultures.
Further investigations are required to rationalize the therapeutic benefit seen using our cannabinoid CB 2 receptor-specific inverse agonists with that observed with cannabinoid CB 2 receptor-specific agonists. We argue that the beneficial therapeutic effect of cannabinoid CB 2 receptor inverse agonists on bone damage is mediated by limiting cell accumulation at the site of insult. Additional mechanisms could be involved in this complex disease, including precursor cell differentiation/proliferation (see above). Other laboratories have described effects of cannabinoid compounds on bone density based on other mechanisms (Sumariwalla et al., 2004; Burstein, 2005; Mbvundula et al., 2005; see Burstein and Zurier, 2004) .
Cannabinoid CB 2 receptor and disease: EAE Another important therapeutic target for cannabinoid CB 2 receptor-specific agents is inflammation of the central nervous system. Like arthritis, this disease involves migration of inflammatory cells to a restricted site, and then action of the cells at that site (Izikson et al., 2002) . Early studies showed that the nonspecific cannabinoid agonist WIN55,212-2 could control spasticity and tremors in a chronic relapsing EAE (Baker et al., 2000) , although this effect is believed to have been mediated by the cannabinoid CB 1 receptor (Pryce and Baker, 2007) . Although initially believed to be uniquely associated with immune cells, functional cannabinoid CB 2 receptors have been found associated with central nervous system tissue (Van Sickle et al., 2005; Beltramo et al., 2006) , and the detectible receptor mRNA increases in activated microglia cells with development of transgenic mice expressing a T-cell receptor transgene specific for the acetylated NH 2 -terminal peptide of myelin basic protein (Ac1-11) bound to I-A u (MBP-TCR) (CD4 þ T-cell-induced EAE model (Maresz et al., 2005) . This effect is believed due to the cannabinoid system within the central nervous system directly suppressing T-cell effector function via the CB 2 receptor (Maresz et al., 2007) . Ni et al. (2004) have shown that the increased leukocyte/endothelium interactions seen in mice following induction of EAE using myelin oligodendrocyte glycoprotein, can be alleviated with the cannabinoid agonist WIN55,212-2 via the CB 2 receptor. Sipe et al. (2005) have extended these studies to human disease, showing the potential linkage of a cannabinoid CB 2 receptor polymorphism associated with autoimmune disorders, including multiple sclerosis. We have carried out preliminary investigations to investigate the role of the cannabinoid CB 2 receptor in inflammatory diseases of the central nervous system, using the cannabinoid CB 2 receptor-deficient mice. We have shown that the ability of a peptide derived from myelin oligodendrocyte glycoprotein ) to elicit EAE (Reich et al., 2005) is diminished in a cannabinoid CB 2 receptor-deficient mouse strain (Lunn et al., 2006b) . The CB 2 receptor-deficient strain showed a significant delay in disease onset, attenuation in clinical disease score and improved survivability (with six of 15 mice dying in the control, but only one of 15 dying in the receptor-deficient group). We have now extended these initial studies to probe the ability of the cannabinoid CB 2 receptor inverse agonist Sch.414319 to modulate EAE in the rat. For these experiments, male Lewis rats were injected with 30 mg of guinea pig spinal cord homogenate in complete Freund's adjuvant into the footpad Radiologic evaluation was performed on the hind paws using Polaroid type 55 films and a microradiographic X-ray unit (Faxitron Hewlett Packard, McMinnville, OR, USA). Each paw was scored for soft tissue swelling (scale 0-3), erosions (scale 0-3), cartilage space changes (scale 0-3) and periostitis (scale 0-3), making for a total possible score of 12. Animals were used in accordance with protocols and guidelines established by our institution's Animal Care and Use Committee, and showed no weight loss during progression of the monoarticular arthritis. mBSA, methylated bovine serum albumin. (Smith et al., 1993) . The animals were treated orally with Sch.414319 in 0.4% methylcellulose starting at day 0 then continuing throughout the 3-week disease course. Animals were evaluated daily for clinical disease score. Figure 5 shows a summation of the results of two independent experiments using at least 24 rats per treatment group. The figure shows that oral administration of 20 and 2 mg kg À1 Sch.414319 significantly modulates the clinical signs of EAE, converting complete hind-limb paralysis to a flaccid tail phenotype. Viewed in another way, we observed that roughly 30% of the vehicle-treated animals showed total limb paralysis, whereas no animals showed total limb paralysis at day 13, when treated with 2 mg kg À1 Sch.414319. The effect appears dose dependent-treatment with 0.2 mg kg À1 Sch.414319 is ineffective.
Conclusions
An ability to control the migration of inflammatory cells to the site of insult is a powerful strategy for the development of immunomodulators. Our work on triaryl bis-sulphones suggest that the cannabinoid CB 2 receptor-specific inverse agonists may serve as such immune modulators. We have demonstrated that this class of compound behaves as inverse agonists in selected biochemical assays, including ligandmediated GTPgS binding, forskolin-stimulated cAMP and in competition binding assays with known cannabinoid agonists/inverse agonists. Recent studies (Gonsiorek et al., 2006) have demonstrated that competition binding in the presence of a radiolabelled triaryl bis-sulphone significantly shifts the observed K i relative to values obtained using an radiolabelled agonist ligand, consistent with the inverse agonist label. However, cell-based bioassays probing the effect of these compounds on the monocyte kinome (Table 3) suggest that the pharmacology of this class of compounds may be more complex. In this review, we have demonstrated that an optimized triaryl bis-sulphone, Sch.414319, modulates cell migration in vivo (Figure 1 ), can modulate bone damage in antigen-induced mono-articular arthritis ( Figure 4 ) and can modulate the clinical signs of EAE in the Lewis rat strain ( Figure 5 ). We have argued that these effects can all result from a control of inflammatory cell migration, and have presented preliminary evidence for a mechanism involving L-plastin phosphorylation could be involved. We have not been the only investigators to identify immunomodulatory activities associated with cannabinoid CB 2 receptor inverse agonists. Iwamura et al. (2001) showed that oral administration of the inverse agonists JTE-907 and SR144528 inhibited carrageenin-induced paw oedema in mice. Ueda et al. (2005) reported that orally administered JTE-907 (0.1-10 mg kg
À1
) and SR144528 (1 mg kg
) significantly inhibited dinitrofluorobenzene-induced ear swelling, with increased cannabinoid CB 2 receptor mRNA expression observed in the inflamed ear. Oka et al. (2005) showed that SR144528 treatment blocked 12-O-tetradecanoylphorbol-13-acetate-induced ear swelling, consistent with an observed decrease in leukotriene B4 production and decrease in neutrophil infiltration into the treated mouse ear. Oka et al. (2006) also observed that ear swelling was suppressed by administration of SR144528 immediately after sensitization (sensitization phase), or upon challenge (elicitation phase) of oxazolone-induced contact dermatitis. This result correlated with suppressed proinflammatory cytokine mRNA expression and attenuated eosinophil recruitment into the treated ear. Further studies, using these and other CB 2 receptorspecific compounds, will be required to resolve the complex pharmacology of cannabinoids and the cannabinoid CB 2 receptor, and to determine the most effective pharmacology to exploit this therapeutic target.
